Solara Active Pharma SciencesSOLARA
SOLARA logo
Fair Value
₹566
Share price16 Dec
₹560.351.0% undervalued intrinsic discount
Loading
1Y-10.27%
7D-2.67%

FDA Approvals And Rising API Demand Will Drive Margin Expansion Over The Long Term

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
16 Dec 25
Views
19
Not Invested

Fair Value vs Share Price

₹566
vs ₹560.351.0% undervalued intrinsic discount
PastFuture-3b26b2017201920212023202520272028Revenue ₹26.1bEarnings ₹4.8b
29.4%
Revenue growth
18.5%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Solara Active Pharma Sciences

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Mediocre balance sheet and slightly overvalued.

Market cap₹27.0b
PB2.2x
Estimated GrowthN/A
Dividend Yield0%
Full analysis

CEO & management

Sandeep Rao
CEO
1.4yrs
CEO Tenure

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.